Back to Results
First PageMeta Content
Acute leukemia / Acute myeloid leukemia / Myeloid leukemia / Design of experiments / Myelodysplastic syndrome / Clinical trial / Medicine / Health / Clinical research


December 10, 2012 Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH DUBLIN, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceu
Add to Reading List

Open Document

File Size: 16,03 KB

Share Result on Facebook

City

Atlanta / Houston / /

Company

Astex Pharmaceuticals Inc. / Astex Pharmaceuticals Astex Pharmaceuticals / Astex Pharmaceuticals / /

Event

FDA Phase / /

Facility

The University of Texas MD Anderson Cancer Center / /

IndustryTerm

pharmaceutical / /

MedicalCondition

pain / acute myelogenous leukemia / high-risk myelodysplastic syndromes / thrombocytopenia / sepsis / mainly febrile neutropenia / /

MedicalTreatment

intravenous infusion / /

Organization

Cancer Medicine Division / American Society of Hematology / Department of Leukemia / University of Texas / /

Person

Hagop M. Kantarjian / /

Position

Chair / Professor / /

Product

Dacogen / 44 patients receiving drug / SGI-110 / /

ProvinceOrState

Texas / California / Georgia / /

URL

www.astx.com / http /

SocialTag